NCT06566209View on ClinicalTrials.gov

FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Subclinical Immune Checkpoint Inhibitor-Induced MyocarditisMyocarditisICI-MyocarditisSolid Malignant TumorHematologic MalignancySubclinical MyocarditisSubclinical ICI-myocarditis
Interventions
DEVICE

Fluorodeoxyglucose - Positron Emission Tomography (FDG-PET)

Receive 18F-FDG PET/CT

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06566209 - FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis | Biotech Hunter | Biotech Hunter